On May 4, 2021 Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, reported that its abstract on the use of comprehensive genomic and transcriptome profiling to predict the benefit of pembrolizumab in patients with advanced cancer was selected for poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place virtually from June 4-8, 2021 (Press release, Strata Oncology, MAY 4, 2021, View Source [SID1234579134]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Abstract title: Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs)
Session title: Poster Session: Developmental Therapeutics—Immunotherapy
Additional meeting information is available on the ASCO (Free ASCO Whitepaper) website, where the abstract will be published on May 19, 2021.